10-Q Filing

INSIGHT MOLECULAR DIAGNOSTICS INC. CIK: 1642380 Q2 2022

Filing Information

Form Type	10-Q
Accession Number	`0001493152-22-022151`
Period End Date	20220630
Filing Date	20220812
Fiscal Year	2022
Fiscal Period	Q2
XBRL Instance	form10-q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 81 Income Statement 84 Cash Flow Statement 106 Stockholders Equity 40 Comprehensive Income 12

Balance Sheet 81 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$35.60M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$44.84M	USD	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$1.80M	USD	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$1.44M	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$904.00K	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$579.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$2.15M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.20M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$39.14M	USD	Point-in-time
Preferred stock no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Total current assets	`AssetsCurrent`	$49.37M	USD	Point-in-time
Preferred stock no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Right-of-use and financing lease assets, net	`FinanceLeaseRightOfUseAsset`	$2.78M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Right-of-use and financing lease assets, net	`FinanceLeaseRightOfUseAsset`	$2.49M	USD	Point-in-time
Machinery and equipment, net, and construction in progress	`MachineryAndEquipmentNetAndConstructionInProgress`	$5.75M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Machinery and equipment, net, and construction in progress	`MachineryAndEquipmentNetAndConstructionInProgress`	$9.09M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Goodwill	`Goodwill`	$18.68M	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Goodwill	`Goodwill`	$9.49M	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Goodwill	`Goodwill`	$18.68M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	230.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	230.00M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$91.25M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$89.34M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$1.70M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$1.70M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	118.61M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	92.23M	shares	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$382.00K	USD	Point-in-time
Common stock, shares, outstanding	`CommonStockSharesOutstanding`	92.23M	shares	Point-in-time
Common stock, shares, outstanding	`CommonStockSharesOutstanding`	118.61M	shares	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$264.00K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$171.05M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$159.56M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.45M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.46M	USD	Point-in-time
Accrued compensation	`AccruedLiabilitiesCurrent`	$3.38M	USD	Point-in-time
Accrued compensation	`AccruedLiabilitiesCurrent`	$2.79M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$4.56M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$2.42M	USD	Point-in-time
Accrued severance from acquisition	`AccruedSeveranceFromAcquisitionCurrent`	$2.31M	USD	Point-in-time
Accrued severance from acquisition	`AccruedSeveranceFromAcquisitionCurrent`	$2.35M	USD	Point-in-time
Accrued liabilities from acquisition	`BusinessCombinationContingentConsiderationLiabilityCurrent`	$609.00K	USD	Point-in-time
Accrued liabilities from acquisition	`BusinessCombinationContingentConsiderationLiabilityCurrent`	$1.39M	USD	Point-in-time
Loans payable, net of deferred financing costs	`LoansPayableCurrent`	$574.00K	USD	Point-in-time
Loans payable, net of deferred financing costs	`LoansPayableCurrent`	$1.31M	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$819.00K	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$839.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.15M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.12M	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$3.54M	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$3.13M	USD	Point-in-time
Contingent consideration liabilities	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$65.67M	USD	Point-in-time
Contingent consideration liabilities	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$76.68M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$94.35M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$82.95M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, no par value, 230,000 shares authorized; 118,609 and 92,232 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	`CommonStockValue`	$252.95M	USD	Point-in-time
Common stock, no par value, 230,000 shares authorized; 118,609 and 92,232 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	`CommonStockValue`	$289.65M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$31.00K	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$37.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-206.44M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-187.77M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$106.63M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$102.67M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$83.24M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$65.22M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$56.97M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$33.48M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$171.05M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$159.56M	USD	Point-in-time

Income Statement 84 line items

Line Item	Tag	Value	Unit	Period
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.49M	USD	2 Qtrs
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$2.07M	USD	1 Quarter
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$2.03M	USD	1 Quarter
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.15M	USD	2 Qtrs
Cost of revenues	`CostOfRevenue`	$2.09M	USD	2 Qtrs
Cost of revenues	`CostOfRevenue`	$2.43M	USD	2 Qtrs
Cost of revenues	`CostOfRevenue`	$1.35M	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$1.41M	USD	1 Quarter
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$1.91M	USD	2 Qtrs
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$976.00K	USD	1 Quarter
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$1.07M	USD	1 Quarter
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$1.38M	USD	2 Qtrs
Gross profit	`GrossProfit`	$-314.00K	USD	1 Quarter
Gross profit	`GrossProfit`	$-315.00K	USD	2 Qtrs
Gross profit	`GrossProfit`	$-394.00K	USD	1 Quarter
Gross profit	`GrossProfit`	$-847.00K	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$5.57M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$10.70M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$2.54M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$5.90M	USD	2 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$3.52M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$4.93M	USD	2 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$2.67M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$6.76M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$11.16M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$7.93M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$12.70M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$5.51M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-6.36M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.09M	USD	2 Qtrs
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$30.00K	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-11.02M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$17.61M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$24.61M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$8.25M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$13.17M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-18.46M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-24.93M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-8.56M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-13.57M	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNet`	$-117.00K	USD	2 Qtrs
Interest expense, net	`InterestIncomeExpenseNet`	$-21.00K	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNet`	$-51.00K	USD	2 Qtrs
Interest expense, net	`InterestIncomeExpenseNet`	$-49.00K	USD	1 Quarter
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$5.00K	USD	1 Quarter
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$173.00K	USD	1 Quarter
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-325.00K	USD	2 Qtrs
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$386.00K	USD	2 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	2 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-270.00K	USD	2 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	2 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	$1.14M	USD	1 Quarter
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	$1.14M	USD	2 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$278.00K	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$242.00K	USD	2 Qtrs
Other income, net	`OtherNonoperatingIncomeExpense`	$18.00K	USD	2 Qtrs
Other income, net	`OtherNonoperatingIncomeExpense`	$16.00K	USD	1 Quarter
Total other expenses, net	`NonoperatingIncomeExpense`	$1.16M	USD	2 Qtrs
Total other expenses, net	`NonoperatingIncomeExpense`	$262.00K	USD	1 Quarter
Total other expenses, net	`NonoperatingIncomeExpense`	$1.28M	USD	1 Quarter
Total other expenses, net	`NonoperatingIncomeExpense`	$-134.00K	USD	2 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-8.30M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-18.59M	USD	2 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-23.77M	USD	2 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-12.29M	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-1.79M	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-9.36M	USD	2 Qtrs
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	2 Qtrs
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-14.41M	USD	2 Qtrs
NET LOSS	`NetIncomeLoss`	$-18.59M	USD	2 Qtrs
NET LOSS	`NetIncomeLoss`	$-10.49M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-8.30M	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasic`	$-0.17	USD	2 Qtrs
Net loss per share: basic and diluted	`EarningsPerShareBasic`	$-0.07	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasic`	$-0.12	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasic`	$-0.18	USD	2 Qtrs
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfSharesOutstandingBasic`	85.96M	shares	2 Qtrs
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfSharesOutstandingBasic`	102.70M	shares	2 Qtrs
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfSharesOutstandingBasic`	113.04M	shares	1 Quarter
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfSharesOutstandingBasic`	89.76M	shares	1 Quarter

Cash Flow Statement 106 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-14.41M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-18.59M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-10.49M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-8.30M	USD	1 Quarter
Depreciation expense	`Depreciation`	$671.00K	USD	2 Qtrs
Depreciation expense	`Depreciation`	$327.00K	USD	2 Qtrs
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$1.38M	USD	2 Qtrs
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$1.90M	USD	2 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	2 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-270.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$3.29M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$4.24M	USD	2 Qtrs
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$5.00K	USD	1 Quarter
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$173.00K	USD	1 Quarter
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-325.00K	USD	2 Qtrs
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$386.00K	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$33.00K	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$11.00K	USD	2 Qtrs
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-6.36M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.09M	USD	2 Qtrs
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$30.00K	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-11.02M	USD	2 Qtrs
Change in fair value of Series A redeemable convertible preferred stock second tranche obligation	`ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation`	$33.00K	USD	2 Qtrs
Change in fair value of Series A redeemable convertible preferred stock second tranche obligation	`ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation`	$-305.00K	USD	2 Qtrs
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-9.36M	USD	2 Qtrs
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	-	USD	2 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	2 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	$1.14M	USD	1 Quarter
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	$1.14M	USD	2 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	1 Quarter
Accrued severance from Chronix Biomedical acquisition	`AccruedSeveranceFromChronixBiomedicalAcquisition`	$-2.45M	USD	2 Qtrs
Accrued severance from Chronix Biomedical acquisition	`AccruedSeveranceFromChronixBiomedicalAcquisition`	-	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$365.00K	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$817.00K	USD	2 Qtrs
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$218.00K	USD	2 Qtrs
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-94.00K	USD	2 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$773.00K	USD	2 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$103.00K	USD	2 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-766.00K	USD	2 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$239.00K	USD	2 Qtrs
Accrued severance and liabilities from Chronix Biomedical acquisition	`AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition`	$817.00K	USD	2 Qtrs
Accrued severance and liabilities from Chronix Biomedical acquisition	`AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition`	-	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-24.57M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-17.89M	USD	2 Qtrs
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$607.00K	USD	2 Qtrs
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	2 Qtrs
Acquisition of Razor Genomics asset, net of cash acquired	`AcquisitionOfRazorGenomicsAssetNetOfCashAcquired`	-	USD	2 Qtrs
Acquisition of Razor Genomics asset, net of cash acquired	`AcquisitionOfRazorGenomicsAssetNetOfCashAcquired`	$6.65M	USD	2 Qtrs
Acquisition of Chronix Biomedical, net of cash acquired	`AcquisitionOfChronixBiomedicalNetOfCashAcquired`	$4.46M	USD	2 Qtrs
Acquisition of Chronix Biomedical, net of cash acquired	`AcquisitionOfChronixBiomedicalNetOfCashAcquired`	-	USD	2 Qtrs
Construction in progress and purchases of furniture and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.45M	USD	2 Qtrs
Construction in progress and purchases of furniture and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.68M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-2.68M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-13.17M	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$1.60M	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	-	USD	2 Qtrs
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$65.26M	USD	2 Qtrs
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$32.81M	USD	2 Qtrs
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$389.00K	USD	2 Qtrs
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$2.68M	USD	2 Qtrs
Proceeds from sale of redeemable convertible Series A preferred shares	`ProceedsFromSaleOfRedeemableConvertibleSeriesPreferredShares`	-	USD	2 Qtrs
Proceeds from sale of redeemable convertible Series A preferred shares	`ProceedsFromSaleOfRedeemableConvertibleSeriesPreferredShares`	$4.88M	USD	2 Qtrs
Financing costs to issue redeemable convertible Series A preferred shares	`FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares`	-	USD	2 Qtrs
Financing costs to issue redeemable convertible Series A preferred shares	`FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares`	$93.00K	USD	2 Qtrs
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions`	$6.48M	USD	2 Qtrs
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions`	$31.00K	USD	2 Qtrs
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	$203.00K	USD	2 Qtrs
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	$1.00K	USD	2 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	2 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$823.00K	USD	2 Qtrs
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	$37.00K	USD	2 Qtrs
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	-	USD	2 Qtrs
Repayment of loan payable	`RepaymentsOfDebt`	$750.00K	USD	2 Qtrs
Repayment of loan payable	`RepaymentsOfDebt`	$750.00K	USD	2 Qtrs
Repayment of financing lease obligations	`RepaymentOfFinancingLeaseObligations`	$7.00K	USD	2 Qtrs
Repayment of financing lease obligations	`RepaymentOfFinancingLeaseObligations`	$84.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$70.42M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$36.48M	USD	2 Qtrs
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$39.36M	USD	2 Qtrs
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$9.23M	USD	2 Qtrs
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$48.20M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$46.54M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$37.30M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$48.20M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$46.54M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$37.30M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	$70.00K	USD	2 Qtrs
Cash paid for interest	`InterestPaidNet`	$21.00K	USD	2 Qtrs
Common stock issued for acquisition of Razor Genomics asset	`StockIssued1`	$5.76M	USD	2 Qtrs
Common stock issued for acquisition of Razor Genomics asset	`StockIssued1`	-	USD	2 Qtrs
Deferred tax liability generated from the acquisition of Razor Genomics asset	`DeferredTaxLiabilityGeneratedFromAcquisitionOfRazorGenomicsAsset`	-	USD	2 Qtrs
Deferred tax liability generated from the acquisition of Razor Genomics asset	`DeferredTaxLiabilityGeneratedFromAcquisitionOfRazorGenomicsAsset`	$7.56M	USD	2 Qtrs
Common stock issued for acquisition of Chronix Biomedical	`CommonStockIssuedForAcquisitionOfChronixBiomedical`	$3.30M	USD	2 Qtrs
Common stock issued for acquisition of Chronix Biomedical	`CommonStockIssuedForAcquisitionOfChronixBiomedical`	-	USD	2 Qtrs
Deferred tax liability generated from the acquisition of Chronix	`DeferredTaxLiabilityGeneratedFromAcquisitionOfChronix`	-	USD	2 Qtrs
Deferred tax liability generated from the acquisition of Chronix	`DeferredTaxLiabilityGeneratedFromAcquisitionOfChronix`	$1.79M	USD	2 Qtrs
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	$42.30M	USD	2 Qtrs
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	-	USD	2 Qtrs
Assumed liability from Chronix Acquisition	`AssumedLiabilityFromChronixAcquisition`	-	USD	2 Qtrs
Assumed liability from Chronix Acquisition	`AssumedLiabilityFromChronixAcquisition`	$9.29M	USD	2 Qtrs
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability`	$1.33M	USD	2 Qtrs
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability`	$9.00K	USD	2 Qtrs

Stockholders Equity 40 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$106.63M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$102.67M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$83.24M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$65.22M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$56.97M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$33.48M	USD	Point-in-time
Net Loss	`NetIncomeLoss`	$-14.41M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-18.59M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-10.49M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-8.30M	USD	1 Quarter
Foreign currency translation adjustment	`AdjustmentstoForeignCurrencyTranslation`	$-7.00K	USD	1 Quarter
Foreign currency translation adjustment	`AdjustmentstoForeignCurrencyTranslation`	$-6.00K	USD	2 Qtrs
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$3.29M	USD	2 Qtrs
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$2.00M	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$4.24M	USD	2 Qtrs
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$2.23M	USD	1 Quarter
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts	`StockIssuedDuringPeriodValueIssuanceOfCommonSharesIncludingAtthemarketTransactionsNetOfFinancingCostsAndUnderwritingDiscounts`	$32.42M	USD	1 Quarter
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts	`StockIssuedDuringPeriodValueIssuanceOfCommonSharesIncludingAtthemarketTransactionsNetOfFinancingCostsAndUnderwritingDiscounts`	$68.87M	USD	2 Qtrs
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts	`StockIssuedDuringPeriodValueIssuanceOfCommonSharesIncludingAtthemarketTransactionsNetOfFinancingCostsAndUnderwritingDiscounts`	$32.45M	USD	2 Qtrs
Shares issued upon vesting of RSU, net of shares retired to pay employees taxes	`SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes`	$-37.00K	USD	1 Quarter
Shares issued upon vesting of RSU, net of shares retired to pay employees taxes	`SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes`	-	USD	2 Qtrs
Shares issued upon vesting of RSU, net of shares retired to pay employees taxes	`SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes`	$-37.00K	USD	2 Qtrs
Shares issued upon vesting of RSU, net of shares retired to pay employees taxes	`SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes`	-	USD	1 Quarter
Issuance of Series A redeemable convertible preferred stock, net of financing costs	`StockIssuedDuringPeriodValueConversionOfUnits`	-	USD	1 Quarter
Issuance of Series A redeemable convertible preferred stock, net of financing costs	`StockIssuedDuringPeriodValueConversionOfUnits`	-	USD	2 Qtrs
Accretion of Series A convertible preferred stock to redemption value	`StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue`	$-72.00K	USD	1 Quarter
Accretion of Series A convertible preferred stock to redemption value	`StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue`	$-72.00K	USD	2 Qtrs
Stock options exercised	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.60M	USD	2 Qtrs
Stock options exercised	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.25M	USD	1 Quarter
Warrants exercised	`StockIssuedDuringPeriodValueWarrantsExercised`	$21.00K	USD	1 Quarter
Warrants exercised	`StockIssuedDuringPeriodValueWarrantsExercised`	$823.00K	USD	2 Qtrs
Issuance of common stock to Chronix Biomedical	`StockIssuedDuringPeriodValueIssuanceOfCommonStockToChronixBiomedical`	$3.30M	USD	1 Quarter
Issuance of common stock to Chronix Biomedical	`StockIssuedDuringPeriodValueIssuanceOfCommonStockToChronixBiomedical`	$3.30M	USD	2 Qtrs
Issuance of common stock to Razor Genomics	`StockIssuedDuringPeriodValueIssuanceOfCommonStockToRazorGenomics`	$5.76M	USD	2 Qtrs
Ending balance, value	`StockholdersEquity`	$106.63M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$102.67M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$83.24M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$65.22M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$56.97M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$33.48M	USD	Point-in-time

Comprehensive Income 12 line items

Line Item	Tag	Value	Unit	Period
NET LOSS	`NetIncomeLoss`	$-14.41M	USD	2 Qtrs
NET LOSS	`NetIncomeLoss`	$-18.59M	USD	2 Qtrs
NET LOSS	`NetIncomeLoss`	$-10.49M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-8.30M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	-	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-7.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	-	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-6.00K	USD	2 Qtrs
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-8.31M	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-18.60M	USD	2 Qtrs
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-14.41M	USD	2 Qtrs
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-10.49M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.